Related Experiment Video
Updated: May 21, 2026
Subretinal Implantation of RPE on a Carrier in Minipigs: Guidelines for Preoperative Preparations, Surgical Techniques, and Postoperative Care
Published on: November 11, 2022
Health services utilization and cost of retinitis pigmentosa
Kevin D Frick1, M Christopher Roebuck, Joshua I Feldstein
1Department of Health Policy and Management, The Johns Hopkins Bloomberg School of Public Health, 624NBroadway,Room 606, Baltimore, MD 21205-1901, USA. kfrick@jhsph.edu
Objective:
To estimate annual per-patient health services utilization and costs of retinitis pigmentosa (RP) in the United States.
Methods:
A retrospective claims analysis of patients with RP (N = 2990) and a 1:1 exactly matched cohort of non-RP patients was conducted using the MarketScan Commercial and Medicare Supplemental Databases. Individuals were continuously enrolled in a commercial health plan or employer-sponsored health insurance for at least 1 year. The following annual outcomes were analyzed using nonlinear multivariate models: inpatient hospital admissions, inpatient hospital days, emergency department visits, outpatient physician visits, and prescription drug refills and inpatient and outpatient medical, pharmacy, and total health care costs.
Results:
Patients with RP had 0.04 more hospital admissions (P < .001), 0.19 more inpatient hospital days (P < .02), 0.05 more emergency department visits (P < .01), 2.74 more outpatient visits (P < .001), and 2.18 additional prescription drug fills (P < .001) annually compared with their non-RP counterparts. Health care expenditures were significantly higher for patients with RP, who cost $894, $4855, and $452 more for inpatient, outpatient, and pharmacy services, respectively (P < .001). Overall health care costs were $7317 more per patient per year in the RP cohort, with expenditures varying considerably by age.
Conclusions:
Patients with RP consume substantially greater amounts of health services with significantly higher health care costs.
Clinical Relevance:
Treatments that slow, halt, or possibly restore RP-related vision loss may prove cost-effective for payers and society.
